Kim Lawson is a pharmacologist with an international reputation in Drug Discovery Research, gained in academia and multinational pharmaceutical industries (France: Rhone-Poulenc, Recherche Syntex France; Belgium: Sanofi-Labaz; UK: Reckitt & Colman, British Biotech). His research interests and expertise are focused towards i) the identification of novel targets for the development of drugs for the treatment of fibromyalgia & ii) modulation of potassium channels as a therapeutic approach. Kim is regularly invited as a consultant to the pharmaceutical and healthcare industries & affiliated organizations, to talk at public events & scientific conferences and to write 'expert opinion' articles for scientific and clinical journals. He is a member of Advisory Boards to the Fibromyalgia Action UK, in addition to being a Patron to Folly Pogs Fibromyalgia Research UK . Kim is also on the Editorial Board of several international scientific and medical journals.

Fibromyalgia: diagnostic and therapeutic approaches, Neuropathic pain and potassium channels, Pharmacology of potassium channels, Drug safety and Torsade de Pointe.